title: Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.
abstract: BACKGROUND
  Tranilast is a therapeutic agent used in treatment of allergic diseases. It has been reported previously that tranilast has antitumour effects on prostate cancer cells. This study examined whether tranilast has clinical benefit for prostate cancer patients.
  
  
  METHODS
  Twenty-one Japanese patients with advanced castration-resistant prostate cancer (CRPC) were administered tranilast orally.
  
  
  RESULTS
  All patients had already been treated with combined androgen blockade followed by one or more salvage therapies and their prostate-specific antigen (PSA) continued to increase before starting tranilast. Median follow-up time was 14 months and median tranilast treatment time was 5 months. PSA progression was inhibited in 5 CRPC patients with bone metastasis. The survival rates at 12 and 24 months were 74.5% and 61.5%, respectively.
  
  
  CONCLUSIONS
  Although this study involved only pilot data, it indicates that tranilast may improve the prognosis of patients with advanced CRPC.
authors.affiliation: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
authors.forename: Kouji
authors.initials: K
authors.lastname: Izumi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizokami
authors.forename: Takashi
authors.initials: T
authors.lastname: Shima
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Narimoto
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Kobori
authors.forename: Yuji
authors.initials: Y
authors.lastname: Maeda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Konaka
authors.forename: Eitetsu
authors.initials: E
authors.lastname: Koh
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000601:surgery; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D062367:ortho-Aminobenzoates / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D062367:ortho-Aminobenzoates; D017430:Prostate-Specific Antigen; C012293:tranilast